EXTENDED CONTENTS

List of figures xv
List of tables xvi
List of contributors xvii
Table of cases xix
Table of legislation xxxviii

1 Competition law and pharma: an economic perspective
Benoît Durand
1. INTRODUCTION 1.1
2. AN R&D INTENSIVE INDUSTRY 1.21
3. THE DETERMINANTS OF R&D INTENSITY IN THE PHARMACEUTICAL INDUSTRY 1.24
4. COMPETITION AND THE PATENT SYSTEM 1.28
5. DELAYING THE ENTRY OF GENERIC 1.35
   A. Strategic use of the patent system 1.41
   B. Product hopping 1.48
   C. Disparaging the generic version 1.52
6. THE EFFECTS OF PARALLEL TRADE 1.55
   A. The development of parallel imports in the EEA 1.60
   B. The effect of parallel imports on prices 1.65
   C. The effect of parallel imports on innovation 1.70
7. THE DEMAND AND PRICING OF PHARMACEUTICAL PRODUCTS 1.78
   A. Demand for pharmaceuticals: institutional details 1.80
   B. Countervailing buyer power in the pharmaceutical industry 1.84
   C. In-hospital and out-of-hospital pricing 1.93

2 Reverse payments: an EU and US perspective
Frank Maier-Rigaud, Nathan Blalock and Oliver Gannon
1. INTRODUCTION 2.1
   A. Overview of recent investigations by competition authorities 2.6
   B. Existence of beneficial reverse payment settlements 2.10
   C. Effects-based analysis of restrictions is required in the assessment of reverse payment settlements 2.12
2. SETTLEMENT AS THE OUTCOME OF IMPERFECT INFORMATION 2.15
3. WHAT ARE REVERSE PAYMENT SETTLEMENTS? 2.19
4. THE INCENTIVES OF ORIGINATORS AND GENERIC COMPANIES TO SETTLE 2.23
   A. Originators face numerous threats to profits prior to patent expiration 2.25
   B. Options for generic companies 2.46
5. FACT-SPECIFIC INQUIRY REQUIRED TO DETERMINE ANTICOMPETITIVENESS OF REVERSE PAYMENT SETTLEMENTS 2.51
   A. How do generic companies and originators evaluate the decision to enter into reverse payment settlements? An economic assessment 2.51
   B. How are the competitive effects of patent settlements without value transfers evaluated? 2.60
   C. How are the competitive effects of a reverse payment settlement evaluated with value transfers? 2.64
6. THE EUROPEAN APPROACH 2.77
   A. Overview of the regulatory assessment in Europe 2.77
   B. The Pharmaceutical Sector Inquiry 2.84

Pablo Figueroa and Alejandro Guerrero - 9781785362613
Downloaded from Elgar Online at 12/04/2021 01:10:45AM
via free access
EXTENDED CONTENTS

C. Annual monitoring reports 2.87
D. Reverse payment investigations 2.94
E. Summary of precedent cases 2.129
7. THE US APPROACH POST-ACTAVIS 2.132
   A. The Actavis ruling 2.132
   B. Different legal assessments prior to the Supreme Court judgment 2.134
   C. The Supreme Court Actavis ruling compared with the EU approach 2.137
   D. The FTC’s monitoring of reverse payment settlements 2.140
   E. The effects of the Actavis ruling on reverse payment settlement lawsuits 2.143
8. CONCLUSION 2.153

3 Article 101 TFEU: horizontal cooperation agreements in the pharmaceutical sector
Soledad Blanco Thomas, Lilia Luchianov and Thomas Weck
1. INTRODUCTION 3.1
2. THE APPLICABLE EU COMPETITION RULES 3.6
   A. Article 101 TFEU 3.10
   B. Applicable EU regulations, guidelines and notices relevant for the assessment of horizontal cooperation 3.26
   C. Safe harbours, de minimis notice and block exemptions 3.28
   D. Ancillary restraints 3.44
   E. Individual assessment 3.46
3. THE RELEVANCE OF SECTOR INQUIRIES AND OTHER STUDIES ON COMPETITION IN THE PHARMACEUTICAL SECTOR 3.51
   A. EU Commission’s sector inquiries 3.52
   B. National sector inquiries and studies 3.60
4. SPECIFIC ISSUES OF HORIZONTAL AGREEMENTS IN THE PHARMACEUTICAL SECTOR 3.69
   A. Preliminary concepts 3.73
   B. Patent settlement agreements 3.95
   C. Co-promotion agreements 3.180
   D. Market sharing agreements 3.205
   E. Co-marketing agreements 3.217
   F. Agreements concerning the use of the patent system 3.227
   G. Other horizontal agreements 3.236
5. COMPETITION IN NEW PHARMACEUTICAL AREAS: BIOLOGICAL AND BIOSIMILAR MEDICINES 3.262

4 The competitive assessment of IP licensing agreements in the pharmaceutical sector
Pierre Moullet
1. INTRODUCTION 4.1
2. COMPETITION ENFORCEMENT IN INNOVATIVE INDUSTRIES 4.7
   A. Static v. dynamic competition 4.7
   B. Relationships between competition and IP law 4.12
3. APPLICATION OF ARTICLE 101 TFEU TO TECHNOLOGY LICENSING AGREEMENTS 4.19
   A. Within the TTBER 4.20
   B. Outside the TTBER 4.42

5 Article 102 TFEU: patent filings as an abuse of dominant position after AstraZeneca: the patent–antitrust interface under a new perspective
Francisco Hernández
1. INTRODUCTION 5.1
2. THE APPLICATION OF ARTICLE 102 TFEU TO PATENT RIGHTS: THE TRADITIONAL APPROACH 5.14
3. THE NEW ANTITRUST ACTIVISM IN THE PHARMACEUTICAL MARKETS 5.27
   A. The Pharmaceutical Sector Inquiry, Final Report 5.28
   B. The judgment of the Court of Justice in AstraZeneca 5.36
   C. The Pfizer case 5.45
4. EUROPEAN COMPETITION LAW IN THE TWENTY-FIRST CENTURY: THE FRAMEWORK FOR A NEW PATENT–ANTITRUST INTERFACE 5.54
5. THE APPLICATION OF ARTICLE 102 TO PATENT FILINGS UP TO DATE: THE WEAKNESS
OF THE ASTRAZENECA APPROACH 5.76
6. CONCLUSION: THE PHARMACEUTICAL MARKET EXPERIENCE – A NEW FRAME
FOR THE IP–ANTITRUST INTERFACE IN EUROPE? 5.92

6 Mergers in the pharmaceutical sector
Pablo Figueroa and Alejandro Guerrero

1. INTRODUCTION 6.1
2. MARKET DEFINITION 6.2
   A. Product market definition for finished dose pharmaceutical products 6.4
   B. Markets upstream and downstream from finished pharmaceuticals 6.31
3. GEOGRAPHIC MARKET DEFINITION 6.40
   A. Finished pharmaceuticals 6.40
   B. Markets upstream of finished pharmaceuticals 6.42
   C. Markets downstream of finished pharmaceuticals 6.43
4. COMPETITIVE ANALYSIS IN THE PHARMACEUTICAL SECTOR 6.45
   A. Preliminary considerations 6.45
   B. The Commission’s approach to affected markets 6.47
   C. Key competitive drivers in the pharmaceutical markets 6.48
   D. Remedies and commitments in merger control 6.61
5. CONCLUSIONS 6.67

7 Mergers in the medical devices sector
Jan Heithecker

1. INTRODUCTION AND OVERVIEW 7.1
2. MARKET DEFINITION 7.6
   A. Introduction and overview 7.6
   B. In-vitro diagnostics devices 7.13
   C. Diagnostic imaging devices 7.25
   D. Orthopaedic devices 7.33
   E. Cardiovascular devices 7.43
   F. Other medical capital goods 7.50
   G. Consumable medical devices 7.61
   H. Geographic market definition 7.78
3. COMPETITIVE ASSESSMENT 7.83
   A. Introduction and overview 7.83
   B. Horizontal concerns 7.89
   C. Non-horizontal concerns 7.106

8 Antitrust practices in pharmaceutical public procurement
Antonio Miño López

1. INTRODUCTION 8.1
2. BID RIGGING: CONCEPT AND ESSENTIAL FEATURES 8.6
   A. Concept: paradigm of cartels 8.6
   B. Restriction by object 8.10
   C. Unifying purpose and stability 8.17
   D. Massive harmful potential 8.20
   E. The non bis in idem principle 8.22
   F. Public policies inducing parallel behaviour: the Ethicon case 8.27
3. TYPES OF COLLUSIVE PRACTICES IN THE PUBLIC PROCUREMENT OF DRUGS AND
   RELATED MARKETS 8.32
   A. Introduction 8.32
   B. Information exchange 8.39
   C. Price fixing 8.42
4. ABUSE OF DOMINANT POSITION 8.124
   A. Introduction 8.124
   B. Market definition 8.127
   C. Dominant position 8.144
   D. Abusive practices 8.153
5. ANTITRUST LIABILITY OF CONTRACTING AUTHORITIES 8.184
   A. ECJ’s FENIN/Selex doctrine: dismissal of liability on the basis of the
      “not-for-the-market” use of the purchased products 8.184
   B. Different national solutions 8.192
   C. United Kingdom singularity 8.205

6. IS THERE ANY WAY TO AVOID BID RIGGING? 8.213

7. CONCLUSIONS 8.218

---

9 EU trade law and pharmaceuticals
Pascale Hecker
1. INTRODUCTION 9.1
2. BACKGROUND: TRIPS AND ACCESS TO ESSENTIAL MEDICINES 9.9
   A. Harmful consequences of the entry into force of TRIPS for access to essential
      medicines in developing countries 9.10
   B. The Doha Declaration and the Waiver Decision: an attempt at mitigating the
      harmful effects of TRIPS 9.14
   C. Willingness to impose TRIPS-plus obligations on developing countries 9.19
3. AN ANALYSIS OF EU TRADE MEASURES THAT FAVOUR IP PROTECTION OVER
   ACCESS TO ESSENTIAL MEDICINES 9.20
   A. EU rules on customs enforcement of IP rights 9.21
   B. The EU-India free trade agreement: an example of EU’s policy with regard to the
      inclusion of IP chapters in bilateral trade agreements 9.32
4. AN ANALYSIS OF EU TRADE MEASURES THAT FAVOUR ACCESS TO ESSENTIAL
   MEDICINES OVER IP PROTECTION 9.43
   A. Regulation 953/2003 setting up a tiered-pricing mechanism: a very seldom used
      mechanism 9.44
   B. Regulation 816/2006 on compulsory licence of generic medicines: an unused
      mechanism 9.51
5. CONCLUSION 9.54

---

10 The pharmaceutical sector and parallel trade
Edurne Navarro Varona and Cristina Caballero Candelario
1. THE PHARMACEUTICAL SECTOR AND PARALLEL TRADE 10.1
   A. Introduction 10.1
   B. Disparate prices and access to pharmaceutical products 10.19
   C. Concept of parallel trade 10.37
   D. Parallel trade in the pharmaceutical sector and competition law 10.47
2. THE ECONOMICS OF PARALLEL TRADE 10.76
   A. Parallel trade and consumers’ welfare 10.76
   B. Parallel trade and innovation 10.96
3. CONCLUSION 10.104

---

11 Free movement and competition in the European market for pharmaceuticals
Pedro Caro de Sousa
1. INTRODUCTION 11.1
2. THE STRUCTURE OF THE EUROPEAN MARKET FOR PHARMACEUTICAL PRODUCTS 11.4
   A. Supply side 11.7
   B. Demand side 11.21
3. FREE MOVEMENT LAW AND PHARMACEUTICAL PRODUCTS 11.26
   A. Supply side 11.28
   B. Demand side 11.41
   4. CONCLUSIONS – FREE MOVEMENT AND COMPETITION IN PHARMACEUTICALS 11.54

---

12 IP law and pharmaceuticals: patents and supplementary protection certificates in
the pharmaceutical sector
Rais Amils
1. INTRODUCTION 12.1
2. PATENTS IN THE PHARMACEUTICAL SECTOR 12.7
   A. Routes to apply for a patent 12.12

---

X

Pablo Figueroa and Alejandro Guerrero
9781785362613
Downloaded from Elgar Online at 12/04/2021 01:10:45AM
via free access
B. Requisites of patentability: novelty, inventive step, industrial application and sufficiency of disclosure 12.23
C. Patent infringement: reference made to literal and by equivalence infringement, and to direct and contributory infringement 12.64
D. Exemptions to the patentee’s ius prohibendi: experimental use and Bolar clause 12.79

3. SUPPLEMENTARY PROTECTION CERTIFICATES FOR PHARMACEUTICAL PRODUCTS 12.92
A. Scope of the SPC Regulation
B. Subject-matter of protection and effects of the SPC
C. Conditions to be met in order for an SPC to be granted
D. Duration of an SPC
E. Grounds for the invalidity of an SPC

4. CONCLUSION 12.123

13 The EU regulatory framework for medicinal products for human use
Marc Martens and Nicolas Carbonnelle

1. INTRODUCTION 13.1
2. OVERVIEW OF THE EU PHARMACEUTICAL REGULATORY ENVIRONMENT AND ITS MAIN ADMINISTRATIVE ACTORS 13.7
A. Legal framework
B. Main stakeholders
3. MEDICINAL PRODUCTS AND BORDERLINE PRODUCTS 13.18
A. Definition
B. Borderline products

4. SPECIFIC CATEGORIES OF MEDICINAL PRODUCTS AND THEIR PARTICULARITIES 13.23
A. Biological medicinal products
B. Radiopharmaceuticals
C. Homeopathic medicinal products
D. Herbal medicinal products
E. Traditional herbal medicinal products
F. Paediatrics
G. Orphan drugs

5. MARKET ACCESS FOR MEDICINAL PRODUCTS 13.64
A. Common traits of the procedures: dossier requirements
B. The centralised MA procedure
C. The national routes
D. Term of validity of an MA and renewal
E. Variations and extensions
F. Exceptions to the obligation to obtain a marketing authorisation
G. Scientific advice and protocol assistance
H. Latest developments

6. ABRIDGED PROCEDURES 13.105
A. Generics
B. Biosimilars
C. Bibliographic procedure
D. Informed consent procedure
E. Hybrid procedure

7. CLINICAL TRIALS 13.118
A. Applicable legislation
B. The requirements under Directive 2001/20/EC
C. The new Clinical Trials Regulation

8. PRICING AND REIMBURSEMENT OF MEDICINAL PRODUCTS: A NON-HARMONISED MATTER 13.168
A. General points
B. Provisions relating to pricing
C. Provisions relating to reimbursement schemes
EXTENDED CONTENTS

9. PHARMACOVIGILANCE 13.184
   A. Duties of the Member States and the EMA 13.187
   B. MAH obligations 13.193
10. CONCLUSION AND PERSPECTIVES 13.208

14 Antitrust and the pharmaceutical industry in the United States
    George A. Hay
    1. INTRODUCTION 14.1
    2. REVERSE PAYMENTS 14.6
       A. The first wave of reverse payment cases 14.14
    3. PRODUCT-HOPPING 14.24
       A. The cases 14.28
    4. EXCESSIVE PRICING 14.49
    5. "INVERSION" MERGERS 14.57
    6. PHARMACY-BENEFIT-MANAGER ("PBM") MERGERS 14.59
    7. CONCLUSION 14.64

15 UK competition and trade in the pharma sector
    Paula Riedel
    1. LEGISLATION 15.1
    2. INDUSTRY AND REGULATORY BACKDROP 15.8
    3. COMPETITION ACT 1998 15.16
       A. Napp Pharmaceutical Holdings Limited ("Napp") 15.16
       B. Genzyme Limited ("Genzyme") 15.44
       C. Reckitt Benckiser ("Reckitt Benckiser") 15.60
       D. Paroxetine 15.76
       E. Phenytoin Sodium 15.104
    4. MARKET STUDIES AND MARKET INVESTIGATIONS IN THE PHARMACEUTICAL SECTOR 15.127
       A. The control of entry regulations and retail pharmacy services in the UK ("Control of Entry market study") 15.128
       B. OFT market study: the Pharmaceutical Price Regulation Scheme ("PPRS market study") 15.136
       C. OFT market study: Medicines Distribution ("Medicines Distribution") 15.144

16 Competition law and pharma: China
    Andrew L. Foster
    1. COMPETITION LAW IN CHINA 16.1
    2. RELEVANT COMPETITION AND PHARMACEUTICAL REGULATORY REGIMES 16.4
       A. Relevant competition legislation and extraterritorial application 16.4
       B. Competition enforcement in China 16.7
       C. Regulatory pharmaceutical pricing regime in China 16.14
    3. ANTICOMPETITIVE AGREEMENTS BETWEEN COMPETITORS (HORIZONTAL) 16.15
       A. Relevant legislation 16.15
       B. Enforcement and penalties 16.22
       C. Significant enforcement activity in the pharmaceutical industry 16.26
    4. ANTICOMPETITIVE AGREEMENTS BETWEEN TRADING PARTNERS (VERTICAL) 16.30
       A. Relevant legislation 16.30
       B. Enforcement and penalties 16.35
       C. Significant enforcement activity 16.39
    5. MARKET DOMINANCE 16.48
       A. Relevant legislation 16.48
       B. Significant enforcement activities in the pharmaceutical industry 16.66
    6. INVESTIGATIONS OF PHARMACEUTICAL PRICING BEHAVIOUR 16.73
       A. Relevant legislation 16.74
       B. Recent NDRC enforcement activity 16.92
       C. Other recent national and local enforcement activities 16.98
    7. ADMINISTRATIVE MONOPOLY 16.102
       A. Relevant legislation 16.102
       B. Significant enforcement activity 16.106
8. MERGER CONTROL 16.109
   A. Relevant legislation 16.109
   B. Significant enforcement activities in the pharmaceutical industry 16.127

17 Competition law and pharma: Spain
   Helmut Brokelmann and Mariarosaria Ganino
   1. INTRODUCTION 17.1
   2. SPANISH COMPETITION LAW 17.2
   3. SPANISH PHARMACEUTICAL LEGISLATION 17.10
   4. APPLICABILITY OF THE COMPETITION RULES TO THE PHARMACEUTICAL SECTOR 17.21
   5. APPLICATION OF ARTICLES 101 TFEU AND 1 SCA 17.28
      A. Horizontal agreements 17.29
      B. Vertical agreements: restrictions of parallel trade 17.42
   6. APPLICATION OF ARTICLES 102 TFEU AND 2 SCA 17.54
      A. Refusals to supply 17.55
      B. Conduct limiting the entry of generics 17.64
      C. Other unilateral conduct 17.72
   7. MERGER CONTROL IN THE PHARMACEUTICAL SECTOR 17.80
      A. Relevant merger legislation and peculiarities of the sector 17.80
      B. Merger decisions in the pharmaceutical sector 17.88

18 The application of competition law in the pharmaceutical sector: challenges for BRICS
   Maria Ioannidou and Ioannis Kokkoris
   1. INTRODUCTION 18.1
   2. DEVELOPING ECONOMIES: BRICS 18.6
      A. Characteristics and specific needs: competition and patent clash 18.6
      B. Competition problems in the pharma sector in developing countries: case law 18.19
   3. A VIEW FROM THE EU AND THE US 18.43
      A. Lessons from EU cases 18.43
      B. Lessons from US cases 18.65
   4. A TAILORED APPROACH FOR BRICS? 18.71
   5. CONCLUSION 18.76

19 Product hopping: the US approach
   Michael A. Carrier
   1. INTRODUCTION 19.1
   2. PRODUCT HOPPING 19.4
      A. Forms 19.6
      B. The Hatch-Waxman Act 19.9
      C. State drug product selection laws 19.16
      D. Timing of generic entry 19.20
   3. JUDICIAL ANALYSIS 19.29
      A. Tricor: hard switch, nuanced analysis 19.32
      B. Walgreen: soft switch, simplistic approach to choice 19.37
      C. Suboxone: hard/soft switches, nuanced analysis 19.41
      D. Doryx: ignored regulatory regime 19.45
      E. Namenda: robust regulatory analysis, improper coercion focus 19.49
   4. CONCLUSION 19.54

20 Marketing data in the pharmaceutical sector: a competition law consideration
   Pedro Callol
   1. INTRODUCTION: DATA AND ITS KEY COMPETITIVE ROLE 20.1
      A. Outline of this chapter 20.1
      B. The rise of data as a key competitive input 20.2
      C. Pharmaceutical marketing related activities 20.12
   2. RELEVANT MARKET ANALYSIS IN COMPETITION PRECEDENTS RELATED TO PHARMACEUTICAL MARKETING DATA 20.14
   3. BUSINESS STRATEGIES RELATED TO DATA AND COMPETITION LAW 20.23
      A. Areas of competitive concern surrounding data 20.23
EXTENDED CONTENTS

B. Agreements and concerted practices aimed at restricting third party access to pharmaceutical marketing data 20.25
C. Unilateral conduct aimed at restricting third party access to pharmaceutical marketing data 20.25
4. DATA AND MERGER CONTROL 20.43
A. The issue of merger control thresholds 20.43
B. Data in merger control matters 20.49
5. CONCLUSION 20.50

Index 761